Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-SHH (also known as OncoMedix) is a radiolabeled recombinant sonic hedgehog (SHH) protein conjugated to the bifunctional chelator DOTA and radiolabeled with the positron emitter Gallium-68 (68Ga). Developed by RadioMedix in collaboration with the MD Anderson Cancer Center, it is designed as a diagnostic PET imaging tracer to target the Patched-1 (PTCH1) receptor, which is overexpressed on cancer stem cells. The agent is intended for the non-invasive, real-time detection of Hedgehog pathway activation and the identification of aggressive, stem-cell-rich tumors, particularly in breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-DOTA-SHH.